Cell Therapy Enters the Era of Solid Tumors with a Surge of Aggressive Investments

In 2017, the commercialization of CAR-T therapy marked a significant milestone for cell therapy. This breakthrough ignited a wave of enthusiasm in the field of cell therapy. Numerous start-up companies worldwide entered the arena armed with dreams and funding. Although CAR-T therapy showed promise for hematological malignancies, it faced challenges in treating solid tumors, which constitute approximately 90% of all cancers. However, a new contender called TIL (Tumor-Infiltrating Lymphocyte) therapy is now emerging as a potential solution. With the recent FDA accelerated approval of Iovance's Lifileucel for the treatment of advanced melanoma, a new era of cell therapy for solid tumors has begun, accompanied by a more aggressive race for advancement.

Breaking through after 40 years:

Tumor-infiltrating lymphocytes (TILs) refer to a heterogeneous group of lymphocytes present within the tumor microenvironment, including T cells, B cells, NK cells, macrophages, and myeloid-derived suppressor cells. TILs act as frontline warriors of the immune system, recruited to the tumor site to combat cancer cells. However, their limited quantity and reduced activity hinder their effectiveness against tumors. The key to TIL therapy lies in the ability to manufacture TILs with potent anti-tumor activity outside the patient's body. The process is similar to CAR-T therapy, involving the collection of naturally occurring TILs from tumor tissue, their activation and ex vivo expansion, and subsequent reinfusion into lymphodepleted patients, enabling them to recognize and eliminate tumor cells. Unlike CAR-T therapy, which relies on genetically modified T cells sourced from patients or donors and can only recognize a limited number of tumor cell surface proteins, TILs derived from tumor tissue possess significant advantages against solid tumors. They have the ability to recognize tumor antigens from both intracellular and extracellular sources and exhibit strong infiltration properties and relatively greater safety. These advantages, coupled with the significant potential in tackling solid tumors, have garnered attention for TIL therapy. However, the journey from understanding the mechanism to practical application has been a long one. While TILs were recognized by the National Cancer Institute as early as 1982, it took 40 years for this therapy to finally become a reality in 2024.

Overcoming limitations:

Clinical data for Iovance's Lifileucel demonstrates its effectiveness in treating advanced melanoma patients who have exhausted other treatment options. The C-144-01 clinical trial data supporting the therapy's approval showed an objective response rate of 31%. Although the median duration of response was not reached during the 18.6 months of follow-up, 42% of patients exhibited responses lasting two years or longer. However, like any pioneering therapy, Lifileucel still faces challenges in terms of industrialization and commercialization. Similar to CAR-T therapy, TIL therapy is a highly personalized manufacturing process that requires expansion of cells specific to each patient. This leads to a longer industrialization cycle for TIL therapy, typically taking 6-8 weeks. Iovance has made improvements in the industrialization process, reducing the time to around 22 days. Nevertheless, the extended waiting period is not conducive to patients' timely treatment. Therefore, expediting the industrialization process further is a crucial challenge that pharmaceutical companies must address. Presently, Iovance is exploring the possibilities of industrialization version 3.0, aiming to streamline the manufacturing process while maintaining the therapy's efficacy and safety.

The era of cell therapy for solid tumors:

The FDA's accelerated approval of Lifileucel marks the beginning of a new era in cell therapy, specifically targeting solid tumors. This milestone not only opens new possibilities for patients but also triggers a more aggressive race for advancements in the field. With the success of Lifileucel, other companies and researchers are likely to intensify their efforts to develop and commercialize TIL therapies for various types of solid tumors. The potential of TIL therapy to overcome the challenges faced by CAR-T therapy in solid tumors has attracted significant attention and investment. As the field progresses, further breakthroughs and refinements are expected, ultimately leading to improved outcomes and expanded treatment options for patients with solid tumors.

Cell therapy has entered a new phase with the advent of TIL therapy for solid tumors. The recent FDA approval of Lifileucel has provided a significant boost to this emerging field and set the stage for a more aggressive pursuit of advancements. With its advantages over CAR-T therapy in tackling solid tumors, TIL therapy holds great promise for revolutionizing cancer treatment. Overcoming the challenges of industrialization and commercialization will be critical to its success. As the era of cell therapy for solid tumors unfolds, patients and the medical community eagerly await further progress and breakthroughs in this rapidly evolving field.